Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT

Duodenal Ulcer Induced by Anti-platelet Agent Clinical Trial

Official title: Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study

Status Completed

Clinical Trial Summary

• Primary objective : To evaluate the efficacy of Rapamide in peptic ulcer prevention in patients taking dual antiplatelet agents

• Study Design: Single center, double-blind, randomized-control trial study

• Study drug: Repamipide vs. placebo

• Assessment criteria The patients will be discharged from the study when one of the followings occurred,

1. Peptic ulcer from upper endoscopy at 3 and 6 month follow up

2. Clinical of upper gastrointestinal bleeding with peptic ulcer from upper endoscopy

3. Anemia by CBC at 1,3 ,6,12 month with peptic ulcer from upper endoscopy

4. Evidence of recurrent myocardial infarction from stent thrombosis

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Duodenal Ulcer
• Duodenal Ulcer Induced by Anti-platelet Agent
• Gastric Ulcer Induced by Anti-platelet Agent
• Peptic Ulcer
• Stomach Ulcer
• Ulcer

• NCT number: NCT02166008
• Study type: Interventional
• Source: King Chulalongkorn Memorial Hospital
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: July 2014
• Completion date: June 2018